Crewe Advisors’s Cytek Biosciences CTKB Stock Holding History

Crewe Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-77	Closed	-$1K	–	1077
2022 Q3	$1K	Hold	77	–	–	﹤0.01%	1128
2022 Q2	$1K	Buy	+77	New	+$766	﹤0.01%	1052

Other funds holding CTKB

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Crewe Advisors's CTKB Position: Q4 2022 in Review

Crewe Advisors sold out of Cytek Biosciences (CTKB) in Q4 2022, closing a stake of 77 shares — an estimated $1K sold.

Crewe Advisors first reported a position in CTKB in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 103 funds tracked by Wall St. Rank hold CTKB as of Q4 2022.

Crewe Advisors reported no remaining Cytek Biosciences position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 77 Cytek Biosciences shares in Q4 2022, an estimated $1K.
Crewe Advisors first reported a position in Cytek Biosciences in Q2 2022 and held it in 2 quarters.
Crewe Advisors's Cytek Biosciences position peaked at $1K in Q3 2022.
103 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.